Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab in moderate-to-severe plaque psoriasis (China, Phase 3)
CTR20232852Phase 3Completed
- Sponsor
- UCB
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of bimekizumab in plaque psoriasis, sponsored by UCB. Started Oct 2023; status: completed.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20232852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232852.